CA2324077C - Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor - Google Patents
Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor Download PDFInfo
- Publication number
- CA2324077C CA2324077C CA002324077A CA2324077A CA2324077C CA 2324077 C CA2324077 C CA 2324077C CA 002324077 A CA002324077 A CA 002324077A CA 2324077 A CA2324077 A CA 2324077A CA 2324077 C CA2324077 C CA 2324077C
- Authority
- CA
- Canada
- Prior art keywords
- medicament
- use according
- formestane
- active compound
- breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to the use of a steroidal aromatase inhibitor for producing a medicament formulated for topical use, for preventing and/or treating a mammary carcinoma. The inventive medicament provides a way of avoiding the side effects associated with systematic use. It is therefore possible to carry out a primary preventative treatment or else a secondary preventative treatment after the appearance of a mammary carcinoma.
Description
MEDICAMENT FOR PREVENTING AND/OR TREATING A
MAMMARY CARCINOMA, CONTAINING A STEROIDAL
AROMATASE INHIBITOR
The invention relates to a medicament for the prophylaxis (primary and secondary prophylaxis) and/or treatment of breast cancer.
Breast cancer is the most frequent malignant disease in women. In Germany, breast cancer makes up about 20% of all cases of cancer in women; the incidence at present is about 30,000 new cases of disease per annum. The adjuvant cancer therapy used today does lead to an increase in the survival rate; breast cancer screening and early surgical treatment can also lower the mortality by over 30%. However, since the number of new cases of disease is continuously increasing, the death rate measured over the total population remains the same or increases. Until now, it has barely been possible to affect the number of new cases, as too little is known about triggering factors.
In approximately half of all breast cancers, oestrogen and/or progesterone receptors are found in the cytoplasm. Breast cancers of this type need oestrogen for the proliferation of their cells. Oestrogens act by binding to specific intracel-lular (cytoplasmic) receptors of oestrogen-sensitive cells, into which they are passively introduced by diffusion from the plasma. The binding changes the configuration of the re-ceptor protein. The receptor-hormone complex controls both the transcription and the expression of specific genes; the synthesis of growth-promoting and/or growth-inhibiting fac-tors caused thereby finally has an effect on cell growth.
By withdrawal of oestrogens, regression of oestrogen-dependent tumours can be achieved. In premenopausal women, the ovaries are the main source of oestrogens. Their surgical removal has therefore beeri carried out since 1896 with breast cancer in the advanced stage (metastasis formation) as a so-called surgical hormone therapy.
In post-menopausal women, the conversion of adrenal andro-gens, especially androstenedione and testosterone, to oes-trone and oestradiol is the main source of oestrogen. The conversion to oestrogens takes place in the muscle and fatty tissue.
In clinical practice, for over twenty years both early and advanced stages of breast cancer have been treated with ta-moxifen or its derivatives (in particular tamoxifen citrate).
Tamoxifen occupies the oestrogen receptors located in the cy-toplasm of the cancer cells and thus causes competitive dis-placement of oestrogens. The complex formed from tamoxifen and the oestrogen receptor prevents the transcription and the expression of genes promoting cell growth, which otherwise is caused by a complex formed from oestrogens and the receptor.
In in-vitro experiments, it has been demonstrated that ta-moxifen also has a growth-inhibiting and, under certain cir-cumstances, even cytostatic effect on cell lines which have no oestrogen receptors. Tamoxifen inhibits protein kinase C
MAMMARY CARCINOMA, CONTAINING A STEROIDAL
AROMATASE INHIBITOR
The invention relates to a medicament for the prophylaxis (primary and secondary prophylaxis) and/or treatment of breast cancer.
Breast cancer is the most frequent malignant disease in women. In Germany, breast cancer makes up about 20% of all cases of cancer in women; the incidence at present is about 30,000 new cases of disease per annum. The adjuvant cancer therapy used today does lead to an increase in the survival rate; breast cancer screening and early surgical treatment can also lower the mortality by over 30%. However, since the number of new cases of disease is continuously increasing, the death rate measured over the total population remains the same or increases. Until now, it has barely been possible to affect the number of new cases, as too little is known about triggering factors.
In approximately half of all breast cancers, oestrogen and/or progesterone receptors are found in the cytoplasm. Breast cancers of this type need oestrogen for the proliferation of their cells. Oestrogens act by binding to specific intracel-lular (cytoplasmic) receptors of oestrogen-sensitive cells, into which they are passively introduced by diffusion from the plasma. The binding changes the configuration of the re-ceptor protein. The receptor-hormone complex controls both the transcription and the expression of specific genes; the synthesis of growth-promoting and/or growth-inhibiting fac-tors caused thereby finally has an effect on cell growth.
By withdrawal of oestrogens, regression of oestrogen-dependent tumours can be achieved. In premenopausal women, the ovaries are the main source of oestrogens. Their surgical removal has therefore beeri carried out since 1896 with breast cancer in the advanced stage (metastasis formation) as a so-called surgical hormone therapy.
In post-menopausal women, the conversion of adrenal andro-gens, especially androstenedione and testosterone, to oes-trone and oestradiol is the main source of oestrogen. The conversion to oestrogens takes place in the muscle and fatty tissue.
In clinical practice, for over twenty years both early and advanced stages of breast cancer have been treated with ta-moxifen or its derivatives (in particular tamoxifen citrate).
Tamoxifen occupies the oestrogen receptors located in the cy-toplasm of the cancer cells and thus causes competitive dis-placement of oestrogens. The complex formed from tamoxifen and the oestrogen receptor prevents the transcription and the expression of genes promoting cell growth, which otherwise is caused by a complex formed from oestrogens and the receptor.
In in-vitro experiments, it has been demonstrated that ta-moxifen also has a growth-inhibiting and, under certain cir-cumstances, even cytostatic effect on cell lines which have no oestrogen receptors. Tamoxifen inhibits protein kinase C
and blocks the activation of calmodulin. It increases the ac-tivity of the killer cells and inhibits suppressor T lymphocytes.
In particular after relatively long treatment, tamoxifen can act on cancer cells as well as oestrogens in a manner which is not known in greater detail and promotes their growth.
Relatively long-lasting tamoxifen treatment can therefore lead, under certain circumstances, to tumour growth. It moreover leads to a risk which is increased by a factor of 3 to 5 of suffering from cancer of the endometrium. In view of the clinical benefits of tamoxifen therapy, this risk is ac-cepted in breast cancer patients.
The systemic treatment of breast cancers with aromatase in-hibitors, in particular 4-hydroxyandrost-4-ene-3,17-dione (INN formestane) is further known. Aromatase is a complex en-zyme system which catalyses the conversion of adrenal andro-gens to oestrone and oestradiol.
Formestane is a derivative of the physiological steroid hor-mone androstenedione and binds competitively to other sub-strates of aromatase. During catalysis, it damages the enzyme molecule irreversibly. Systemic treatment with formestane is likewise used as an antioestrogenic breast cancer therapy.
The invention is based on the object of creating a medicament of the type mentioned at the outset, which is suitable for treatment, and in particular also prophylaxis, of breast can-cer.
The invention achieves this object by formulating a steroidal aromatase inhibitor to give a medicament intended for topical application. The use of antigestagens as an additional con-stituent of the medicament is excluded in the context of the invention.
Some terms used in the context of the invention will first be explained.
According to the invention, steroidal aromatase inhibitors are used as substances inhibiting the formation of oestro-gens. These inhibit oestrogen biosynthesis from the andro-genic precursors, for example the enzymatic conversion of an-drostenedione to oestrone or of testosterone to oestradiol.
Since the two synthesis steps mentioned are mediated by the enzyme system of the aromatase (converting enzyme), aromatase inhibitors are used in the context of the invention. Pre-ferred inhibitors are those which bind to the aromatase and irreversibly damage this. After topical application, they penetrate through the skin and concentrate in the fatty tis-sue.
The medicament according to the invention is intended for topical application. The medicament is applied locally to the skin, the preferably strongly lipophilic active compound is transdermally absorbed and thus brought locally to the in-tended site of action. The active compound concentrates in the periductal fatty tissue. In a long-term treatment, the fatty matter of the treated breast is markedly reduced. This reduction decreases the quantity of oestrogen-forming cells having oestrogen-forming competence. The lipophilicity and hydrophobicity of the active compound has the result that the active compound is exclusively concentrated locally in the fatty tissue and can display no systemic action. Oestrogens are understood as meaning all female sex hormones having an action comparable, for example, to that of oestrone and oes-tradiol.
In particular after relatively long treatment, tamoxifen can act on cancer cells as well as oestrogens in a manner which is not known in greater detail and promotes their growth.
Relatively long-lasting tamoxifen treatment can therefore lead, under certain circumstances, to tumour growth. It moreover leads to a risk which is increased by a factor of 3 to 5 of suffering from cancer of the endometrium. In view of the clinical benefits of tamoxifen therapy, this risk is ac-cepted in breast cancer patients.
The systemic treatment of breast cancers with aromatase in-hibitors, in particular 4-hydroxyandrost-4-ene-3,17-dione (INN formestane) is further known. Aromatase is a complex en-zyme system which catalyses the conversion of adrenal andro-gens to oestrone and oestradiol.
Formestane is a derivative of the physiological steroid hor-mone androstenedione and binds competitively to other sub-strates of aromatase. During catalysis, it damages the enzyme molecule irreversibly. Systemic treatment with formestane is likewise used as an antioestrogenic breast cancer therapy.
The invention is based on the object of creating a medicament of the type mentioned at the outset, which is suitable for treatment, and in particular also prophylaxis, of breast can-cer.
The invention achieves this object by formulating a steroidal aromatase inhibitor to give a medicament intended for topical application. The use of antigestagens as an additional con-stituent of the medicament is excluded in the context of the invention.
Some terms used in the context of the invention will first be explained.
According to the invention, steroidal aromatase inhibitors are used as substances inhibiting the formation of oestro-gens. These inhibit oestrogen biosynthesis from the andro-genic precursors, for example the enzymatic conversion of an-drostenedione to oestrone or of testosterone to oestradiol.
Since the two synthesis steps mentioned are mediated by the enzyme system of the aromatase (converting enzyme), aromatase inhibitors are used in the context of the invention. Pre-ferred inhibitors are those which bind to the aromatase and irreversibly damage this. After topical application, they penetrate through the skin and concentrate in the fatty tis-sue.
The medicament according to the invention is intended for topical application. The medicament is applied locally to the skin, the preferably strongly lipophilic active compound is transdermally absorbed and thus brought locally to the in-tended site of action. The active compound concentrates in the periductal fatty tissue. In a long-term treatment, the fatty matter of the treated breast is markedly reduced. This reduction decreases the quantity of oestrogen-forming cells having oestrogen-forming competence. The lipophilicity and hydrophobicity of the active compound has the result that the active compound is exclusively concentrated locally in the fatty tissue and can display no systemic action. Oestrogens are understood as meaning all female sex hormones having an action comparable, for example, to that of oestrone and oes-tradiol.
5 In the use of aromatase inhibitors known from the prior art, such as formestane, it is intended to transport these to the site of action via the blood circulation. High serum concen-trations of the aromatase inhibitor are aimed at, which, in addition to the desired action in the tumour, can lead to systemic side effects. In view of the severity of the ill-ness, such side effects are accepted in acute therapy in view of the success desired. However, this does not come into con-sideration in the case of a preventive treatment against a still unexisting or clearly detected disease.
According to the invention, however, it is intended to apply the medicament topically immediately on or in the vicinity of the intended site of action. Unlike the prior art, no trans-port via the blood circulation to the intended site of action is aimed at. According to the invention, the result achieved is an adequate local active compound level in the tissue at risk (in prophylaxis) or in the diseased tissue (in therapy) without a noticeable absorption of the active compound taking place in the blood circulation. The crux of the invention is thus not only in the topical application per se, but in the local topical application in such a way that the active com-pound concentrates immediately in the tissue at risk and/or diseased tissue, and not indirectly via the blood circula-tion.
If metastasizing carcinomas are also to be treated and/or prophylaxis is to be carried out against these, the medica-ment according to the invention can be applied topically to the intended site of action in such an amount that a notice-able absorption in the blood circulation additionallv takes place and a serum level thus builds up which also transports the active compound to metastases. In this use too, a local absorption on or in the vicinity of the intended site of ac-tion also primarily takes place.
The medicament can be used for the treatment of breast can-cer. After surgical primary care and, if appropriate, appro-priate adjuvant therapy, this treatment can replace and/or supplement the hitherto customary systemic antioestrogenic therapy.
An important advantage of the invention is the possibility of also using the medicament for breast cancer prophylaxis. A
particularly advantageous possibility of employment is so-called secondary prophylaxis. In female patients in whom a breast cancer is already present, there is a particularly high risk of a further carcinoma in the contralateral breast.
The contralateral breast can then be treated prophylactically with the medicament according to the invention. A secondary prophylactic treatment of the diseased breast to avoid local recurrences is likewise possible.
In the case of so-called high-risk women, primary prophylaxis can be performed. The selection criteria which can be used for such a high-risk group are, for example, the facts that at least one female relative of first degree on the mother's side is or has been suffering from breast cancer on one side before the 45th year of life or bilaterally, or that on the mother's side at least one female relative of first degree and an additional female relative are or have been suffering from breast cancer. Since the local application according to the invention virtually completely avoids possible systemic side effects of the active compound on account of its hydro-phobicity, the indication for primary prophylaxis can be made relatively generously already in the presence of tissue hav-ing a comparatively low or average risk (for example his-tological finding Prechtel II or III). Prophylaxis can be started even if the conventional early diagnosis (palpation finding) is still negative, since this customary early diag-nosis is inadequate and as a rule only detects a breast can-cer when a systemic disease which is barely still curable is already present.
The medicament according to the invention is preferably ap-plied locally and topically over a relatively long period of time (if needed up to lifelong) and application is carried out, for example, once or twice per day.
The active substances are selected from the group consisting of the (preferably lipid-soluble) steroidal aromatase inhibi-tors. On topical application, these lipid-soluble substances penetrate into the fatty tissue and locally prevent the de novo formation of oestrogens from the oestrogen precursors.
For example, steroidal aromatase inhibitors such as 4-hydroxyandrost-4-ene-3,17-dione (formestane), 6-methyleneandrostra-1,4-diene-3,17-dione (exemestane), 10 -(2-propynyl)estr-4-ene-3,17-dione (MDL 18962) and 7-a-substituted androstenedione derivatives can be used.
According to the invention, however, it is intended to apply the medicament topically immediately on or in the vicinity of the intended site of action. Unlike the prior art, no trans-port via the blood circulation to the intended site of action is aimed at. According to the invention, the result achieved is an adequate local active compound level in the tissue at risk (in prophylaxis) or in the diseased tissue (in therapy) without a noticeable absorption of the active compound taking place in the blood circulation. The crux of the invention is thus not only in the topical application per se, but in the local topical application in such a way that the active com-pound concentrates immediately in the tissue at risk and/or diseased tissue, and not indirectly via the blood circula-tion.
If metastasizing carcinomas are also to be treated and/or prophylaxis is to be carried out against these, the medica-ment according to the invention can be applied topically to the intended site of action in such an amount that a notice-able absorption in the blood circulation additionallv takes place and a serum level thus builds up which also transports the active compound to metastases. In this use too, a local absorption on or in the vicinity of the intended site of ac-tion also primarily takes place.
The medicament can be used for the treatment of breast can-cer. After surgical primary care and, if appropriate, appro-priate adjuvant therapy, this treatment can replace and/or supplement the hitherto customary systemic antioestrogenic therapy.
An important advantage of the invention is the possibility of also using the medicament for breast cancer prophylaxis. A
particularly advantageous possibility of employment is so-called secondary prophylaxis. In female patients in whom a breast cancer is already present, there is a particularly high risk of a further carcinoma in the contralateral breast.
The contralateral breast can then be treated prophylactically with the medicament according to the invention. A secondary prophylactic treatment of the diseased breast to avoid local recurrences is likewise possible.
In the case of so-called high-risk women, primary prophylaxis can be performed. The selection criteria which can be used for such a high-risk group are, for example, the facts that at least one female relative of first degree on the mother's side is or has been suffering from breast cancer on one side before the 45th year of life or bilaterally, or that on the mother's side at least one female relative of first degree and an additional female relative are or have been suffering from breast cancer. Since the local application according to the invention virtually completely avoids possible systemic side effects of the active compound on account of its hydro-phobicity, the indication for primary prophylaxis can be made relatively generously already in the presence of tissue hav-ing a comparatively low or average risk (for example his-tological finding Prechtel II or III). Prophylaxis can be started even if the conventional early diagnosis (palpation finding) is still negative, since this customary early diag-nosis is inadequate and as a rule only detects a breast can-cer when a systemic disease which is barely still curable is already present.
The medicament according to the invention is preferably ap-plied locally and topically over a relatively long period of time (if needed up to lifelong) and application is carried out, for example, once or twice per day.
The active substances are selected from the group consisting of the (preferably lipid-soluble) steroidal aromatase inhibi-tors. On topical application, these lipid-soluble substances penetrate into the fatty tissue and locally prevent the de novo formation of oestrogens from the oestrogen precursors.
For example, steroidal aromatase inhibitors such as 4-hydroxyandrost-4-ene-3,17-dione (formestane), 6-methyleneandrostra-1,4-diene-3,17-dione (exemestane), 10 -(2-propynyl)estr-4-ene-3,17-dione (MDL 18962) and 7-a-substituted androstenedione derivatives can be used.
The names mentioned in brackets are the INNs (International nonproprietary names). For the terminology and structure of the substances mentioned, reference is likewise made to the "Rote Liste" and Rompp's chemical encylopaedia.
Until now, the substances mentioned have only been used for the systemic therapy of breast cancer. According to the in-vention, however, the active compound is brought to the in-tended site of application by local application. When using aromatase inhibitors, the invention achieves a reduction of the aromatase activity in the fatty tissue of the breast, i.e. exactly in the position in which a tumour can be formed or grow. On relatively long-term use, the fatty matter of the breast and thus the amount of possible risk tissue is re-duced. Since breast cancers are frequently formed in upper breast quadrants of increased aromatase activity, particu-larly effective prophylaxis is possible there according to the invention.
The use according to the invention of aromatase inhibitors can be employed prophylactically or therapeutically even against those tumours of the breast which are themselves able to produce oestrogen or autocrine/paracrine stimulation. A
lowering of the oestrogen concentration in the plasma barely has an effect on such tumours, but the reduction of the in-tratumoral aromatase concentration to be achieved according to the invention can affect such tumours on account of the use of cell-permeable inhibitors.
Since the active compounds administered according to the in-vention remain localized in the fatty tissue of the breast and display their intended action there on account of their lipid solubility, the side effects induced by systemic appli-cation are eliminated. This reduction or exclusion of side effects allows significantly wider prophylactic use. The me-dicament according to the invention can be applied by pa-tients themselves and frequent visits to the doctor for this purpose are not necessary.
A medicament formulated according to the invention preferably contains formestane.
Formestane derivatives such as, for example, acetylated formestane (for example 4-O-acetylandrost-4-ene-3,17-dione) are likewise preferably utilizable. The acetylation of the formestane increases its hydrophilicity and thus skin pene-tration significantly. Since the acetyl group is hydrolysed under the conditions prevailing in the subcutaneous region after passage through the skin, the actual active compound formestane is formed again in situ. When using such an acety-lated formestane, a precursor of the actual active compound penetrating better through the skin is thus applied and the inventors have recognized that the actual active compound is formed in situ subcutaneously from this precursor.
As a rule, the active compounds used according to the inven-tion are lipid-soluble and highly suitable for topical appli-cation. As already described above, the concentration in the fatty tissue of the breast avoids systemic side effects. To improve the skin penetration, substances known in the prior art which promote this can be added to the medicament accord-ing to the invention, for example hyaluronidases or DMSO
(dimethyl sulphoxide).
The medicament is preferably formulated as an ointment, cream, gel, emulsion or lotion. Formulation as a powder or oil is also conceivable. Formulation bases are familiar to 5 the person skilled in the art from the cosmetic and pharma-ceutical industry and do not need to be explained here in greater detail. For example, vegetable oils and fats such as almond oil, peanut oil, olive oil, peach kernel oil, castor oil, plant extracts, ethereal oils; furthermore vegetable 10 waxes and synthetic and animal oils, fats or waxes; lecithin, lanolin alcohols, carotene, fragrances, mono- or polyhydric alcohols, urea, preservatives and colourants etc. can be used. Formulation as an oil-in-water or water-in-oil emulsion is preferred.
The active compound content of the medicament (the content of substances inhibiting the formation of oestrogens) can be between 0.0001 and 20% by weight, preferably 0.6 and 10% by weight, further preferably 1 and 5% by weight. A customary range is 0.6 to 2% by weight.
If substances are admixed to promote skin penetration absorp-tion, their content, when using hyaluronidases, can be, for example, between 0.01 and 1% by weight, preferably 0.05 and 0.2% by weight; when using DMSO between 1 and 25% by weight, preferably 5 and 10% by weight.
Embodiments of the invention are described below. In the drawing:
Until now, the substances mentioned have only been used for the systemic therapy of breast cancer. According to the in-vention, however, the active compound is brought to the in-tended site of application by local application. When using aromatase inhibitors, the invention achieves a reduction of the aromatase activity in the fatty tissue of the breast, i.e. exactly in the position in which a tumour can be formed or grow. On relatively long-term use, the fatty matter of the breast and thus the amount of possible risk tissue is re-duced. Since breast cancers are frequently formed in upper breast quadrants of increased aromatase activity, particu-larly effective prophylaxis is possible there according to the invention.
The use according to the invention of aromatase inhibitors can be employed prophylactically or therapeutically even against those tumours of the breast which are themselves able to produce oestrogen or autocrine/paracrine stimulation. A
lowering of the oestrogen concentration in the plasma barely has an effect on such tumours, but the reduction of the in-tratumoral aromatase concentration to be achieved according to the invention can affect such tumours on account of the use of cell-permeable inhibitors.
Since the active compounds administered according to the in-vention remain localized in the fatty tissue of the breast and display their intended action there on account of their lipid solubility, the side effects induced by systemic appli-cation are eliminated. This reduction or exclusion of side effects allows significantly wider prophylactic use. The me-dicament according to the invention can be applied by pa-tients themselves and frequent visits to the doctor for this purpose are not necessary.
A medicament formulated according to the invention preferably contains formestane.
Formestane derivatives such as, for example, acetylated formestane (for example 4-O-acetylandrost-4-ene-3,17-dione) are likewise preferably utilizable. The acetylation of the formestane increases its hydrophilicity and thus skin pene-tration significantly. Since the acetyl group is hydrolysed under the conditions prevailing in the subcutaneous region after passage through the skin, the actual active compound formestane is formed again in situ. When using such an acety-lated formestane, a precursor of the actual active compound penetrating better through the skin is thus applied and the inventors have recognized that the actual active compound is formed in situ subcutaneously from this precursor.
As a rule, the active compounds used according to the inven-tion are lipid-soluble and highly suitable for topical appli-cation. As already described above, the concentration in the fatty tissue of the breast avoids systemic side effects. To improve the skin penetration, substances known in the prior art which promote this can be added to the medicament accord-ing to the invention, for example hyaluronidases or DMSO
(dimethyl sulphoxide).
The medicament is preferably formulated as an ointment, cream, gel, emulsion or lotion. Formulation as a powder or oil is also conceivable. Formulation bases are familiar to 5 the person skilled in the art from the cosmetic and pharma-ceutical industry and do not need to be explained here in greater detail. For example, vegetable oils and fats such as almond oil, peanut oil, olive oil, peach kernel oil, castor oil, plant extracts, ethereal oils; furthermore vegetable 10 waxes and synthetic and animal oils, fats or waxes; lecithin, lanolin alcohols, carotene, fragrances, mono- or polyhydric alcohols, urea, preservatives and colourants etc. can be used. Formulation as an oil-in-water or water-in-oil emulsion is preferred.
The active compound content of the medicament (the content of substances inhibiting the formation of oestrogens) can be between 0.0001 and 20% by weight, preferably 0.6 and 10% by weight, further preferably 1 and 5% by weight. A customary range is 0.6 to 2% by weight.
If substances are admixed to promote skin penetration absorp-tion, their content, when using hyaluronidases, can be, for example, between 0.01 and 1% by weight, preferably 0.05 and 0.2% by weight; when using DMSO between 1 and 25% by weight, preferably 5 and 10% by weight.
Embodiments of the invention are described below. In the drawing:
Fig. 1 shows the cytological result of a fatty cell aspirate before use of the medicament according to the inven-tion, Fig. 2 shows the corresponding result after daily use over the course of 3 months.
Example 1 The following constituents were mixed to give a cream:
Urea 10 g Titanium oxide 15 g Crude petroleum jelly 20 g Isopropyl palmitate 10 g Hardened peanut oil 10 g Tween4 80 5 g Formestane 1 g made up with purified water to 100 g Example 2 A gel was prepared from the following constituents:
Ethanol 90% 7.0 g Carbopolx 934 P 7.0 g Triethanolamine 2 g Polysorbate 80 5.0 g Glycerol 3.0 g Formestane 0.75 g purified water to 100 g * trade-mark Example 3 A cream was prepared from the following constituents:
Propylene glycol 25.0 g Isopropyl myristate 6.0 g Sorbitan monostearate 1.0 g Polysorbate 80 2.0 g Cetylstearyl alcohol 6.0 g Stearyl alcohol 2.0 g Glycerol monostearate 1.0 g Hyaluronic acid 0.1 g Formestane 1.5 g purified water to 100 g Example 4 A cream was prepared from the following constituents. The constituents are indicated in this example by their INCI
names.
INCI
Ceteareth-25 3.0 g PEG-4-polyglyceryl 2-stearate 2.0 g Cetearyl alcohol 4.9 g Petrolatum 10.0 g Paraffinum perliquidum 3.0 g Sodium carbomer 400 0.14 g Lactic acid 0.02 g Paraffinum perliquidum 2.0 g Phenoxyethanol, dehydroacetic acid, ben-zoic acid 0.4 g Perfume 0.08 g Formestane 1.5 g made up with water to 100 g The mixture of phenoxyethanol, dehydroacetic acid and benzoic acid mentioned in the formulation is obtainable from SchUlke & Mayr under the name Euxyl* K702.
Example 5 A cream was prepared from the following constituents, which are indicated by their INCI names.
INCI
Ceteareth-25 3.0 g PEG-4-polyglyceryl 2-stearate 2.0 g Cetearyl alcohol 4.9 g Petrolatum. - 10.0 g Paraffinum perliquidum 3.0 g Sodium carbomer 400 0.14 g Lactic acid 0.02 g Paraffinum perliquidum 2.0 g Phenoxyethanol, dehydroacetic acid, ben-zoic acid 0.4 g Perfume 0.08 g 4-acetylandrost-4-ene-3,17-dione (acetylated formestane) 1.5 g made up with water to 100 g * trade-mark Example 6 A clinical test of the recipe according to Example 1 was car-ried out. The findings of oversize breasts and medium-grade mastopathy were present in the 25-year-old volunteer.
A fine needle aspirate of the fatty tissue (0.6 mm puncture needle, fixation in absolute ethanol, staining: May-Grunwald-Giemsa) was withdrawn (Fig. 1). Distended fat cells and ec-centric cell nuclei as a result of a high oestrogen influx are detected.
The volunteer then applied the cream according to Example 1 twice daily over a period of 3 months. Fig. 2 shows the fatty tissue aspirate after this use. A reduction in volume of the fatty tissue ("shrivelled" fat cells in a regular arrange-ment) and an increase in connective tissue is detected due to the aromatase inhibition. The results showed a reduction of the tissue at risk by about 50% and a distinct firming of connective tissue and skin.
Example 1 The following constituents were mixed to give a cream:
Urea 10 g Titanium oxide 15 g Crude petroleum jelly 20 g Isopropyl palmitate 10 g Hardened peanut oil 10 g Tween4 80 5 g Formestane 1 g made up with purified water to 100 g Example 2 A gel was prepared from the following constituents:
Ethanol 90% 7.0 g Carbopolx 934 P 7.0 g Triethanolamine 2 g Polysorbate 80 5.0 g Glycerol 3.0 g Formestane 0.75 g purified water to 100 g * trade-mark Example 3 A cream was prepared from the following constituents:
Propylene glycol 25.0 g Isopropyl myristate 6.0 g Sorbitan monostearate 1.0 g Polysorbate 80 2.0 g Cetylstearyl alcohol 6.0 g Stearyl alcohol 2.0 g Glycerol monostearate 1.0 g Hyaluronic acid 0.1 g Formestane 1.5 g purified water to 100 g Example 4 A cream was prepared from the following constituents. The constituents are indicated in this example by their INCI
names.
INCI
Ceteareth-25 3.0 g PEG-4-polyglyceryl 2-stearate 2.0 g Cetearyl alcohol 4.9 g Petrolatum 10.0 g Paraffinum perliquidum 3.0 g Sodium carbomer 400 0.14 g Lactic acid 0.02 g Paraffinum perliquidum 2.0 g Phenoxyethanol, dehydroacetic acid, ben-zoic acid 0.4 g Perfume 0.08 g Formestane 1.5 g made up with water to 100 g The mixture of phenoxyethanol, dehydroacetic acid and benzoic acid mentioned in the formulation is obtainable from SchUlke & Mayr under the name Euxyl* K702.
Example 5 A cream was prepared from the following constituents, which are indicated by their INCI names.
INCI
Ceteareth-25 3.0 g PEG-4-polyglyceryl 2-stearate 2.0 g Cetearyl alcohol 4.9 g Petrolatum. - 10.0 g Paraffinum perliquidum 3.0 g Sodium carbomer 400 0.14 g Lactic acid 0.02 g Paraffinum perliquidum 2.0 g Phenoxyethanol, dehydroacetic acid, ben-zoic acid 0.4 g Perfume 0.08 g 4-acetylandrost-4-ene-3,17-dione (acetylated formestane) 1.5 g made up with water to 100 g * trade-mark Example 6 A clinical test of the recipe according to Example 1 was car-ried out. The findings of oversize breasts and medium-grade mastopathy were present in the 25-year-old volunteer.
A fine needle aspirate of the fatty tissue (0.6 mm puncture needle, fixation in absolute ethanol, staining: May-Grunwald-Giemsa) was withdrawn (Fig. 1). Distended fat cells and ec-centric cell nuclei as a result of a high oestrogen influx are detected.
The volunteer then applied the cream according to Example 1 twice daily over a period of 3 months. Fig. 2 shows the fatty tissue aspirate after this use. A reduction in volume of the fatty tissue ("shrivelled" fat cells in a regular arrange-ment) and an increase in connective tissue is detected due to the aromatase inhibition. The results showed a reduction of the tissue at risk by about 50% and a distinct firming of connective tissue and skin.
Claims (9)
1. ~Use of a steroidal aromatase inhibitor for the preparation of a medicament formulated for local topical application for the prophylaxis or treatment of mastocarcinoma, where the medicament contains no antigestagens.
2. ~Use according to Claim 1, characterized in that the medicament contains formestane (4-hydroxyandrost-4-ene-3,17-dione) or a pharmacologically active formestane derivative.
3. ~Use according to Claim 2, characterized in that the medicament contains 4-O-acetylandrost-4-ene-3,17-dione.
4. ~Use according to one of Claims 1 to 3, characterized in that the medicament additionally contains substances for promoting skin penetration.
5. ~Use according to Claim 4, characterized in that the medicament contains DMSO.
6. ~Use according to one of Claims 1 to 5, characterized in that the medicament is formulated as an ointment, cream, gel, emulsion or lotion.
7. ~Use according to claim 6, characterized in that the active compound content is 0.0001-20% by weight.
8. ~Use according to claim 7, characterized in that the active compound content is 0.6 - 10% by weight.
9. ~Use according to claim 8, characterized in that the active compound content is 1 - 5% by weight.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98104949A EP0943333A1 (en) | 1998-03-18 | 1998-03-18 | Medicament for the prevention and/or treatment of breast cancer comprising an inhibitor of estrogen synthesis |
| EP98104949.7 | 1998-03-18 | ||
| PCT/EP1999/001374 WO1999047143A1 (en) | 1998-03-18 | 1999-03-03 | Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2324077A1 CA2324077A1 (en) | 1999-09-23 |
| CA2324077C true CA2324077C (en) | 2008-07-29 |
Family
ID=8231611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002324077A Expired - Fee Related CA2324077C (en) | 1998-03-18 | 1999-03-03 | Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP0943333A1 (en) |
| JP (1) | JP4920822B2 (en) |
| KR (1) | KR100778803B1 (en) |
| CN (1) | CN1168448C (en) |
| AT (1) | ATE230995T1 (en) |
| AU (1) | AU751040B2 (en) |
| BR (1) | BR9908885A (en) |
| CA (1) | CA2324077C (en) |
| CZ (1) | CZ292643B6 (en) |
| DE (1) | DE59904042D1 (en) |
| DK (1) | DK1063998T3 (en) |
| ES (1) | ES2190201T3 (en) |
| HU (1) | HU226105B1 (en) |
| ID (1) | ID26965A (en) |
| IL (1) | IL138292A (en) |
| PL (1) | PL343100A1 (en) |
| RU (1) | RU2225206C2 (en) |
| SK (1) | SK285349B6 (en) |
| WO (1) | WO1999047143A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11850451B2 (en) | 2011-01-31 | 2023-12-26 | Lucolas-M.D. Ltd. | Cosmetic compositions and methods for improving skin conditions |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10042411A1 (en) * | 2000-08-30 | 2002-03-28 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for the delivery of exemestane |
| DE10054294A1 (en) * | 2000-11-02 | 2002-05-16 | Heinrich Wieland | Topical treatment for mastalgia |
| JP4524296B2 (en) * | 2007-03-30 | 2010-08-11 | 生化学工業株式会社 | Hair growth promoter |
| DE102007032468A1 (en) | 2007-07-10 | 2009-01-15 | Brätter, Christian, Dr. | Transdermal therapeutic systems containing the active substance anastrozole |
| ES2647566T3 (en) * | 2011-01-31 | 2017-12-22 | Lucolas-M.D. Ltd. | Combinations of aromatase inhibitors and antioxidants |
| JP2014516337A (en) * | 2011-01-31 | 2014-07-10 | ルコラス エム・ディー リミテッド | Cosmetic use |
| EP3666276A1 (en) * | 2018-12-14 | 2020-06-17 | dcic Biopharmaceutical Limited | Medication against estrogen-receptor beta (erbeta) positive breast tumor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235893A (en) * | 1978-05-08 | 1980-11-25 | Brodie Angela M | Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis |
| DE3322285A1 (en) * | 1983-06-18 | 1984-12-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1-ALKYL-ANDROSTA-1,4-DIEN-3,17-DIONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
| FR2558373B1 (en) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | ANTI-ESTROGEN MEDICINAL PRODUCT BASED ON 4-HYDROXYTAMOXIFENE FOR PERCUTANEOUS ADMINISTRATION |
| JPS6345294A (en) * | 1986-04-07 | 1988-02-26 | Shionogi & Co Ltd | Aromatase-inhibiting steroid derivative |
| EP0310542B1 (en) * | 1987-10-01 | 1994-06-08 | Schering Aktiengesellschaft | Antigestagenic and antioestrogenic compounds for the treatment of hormone-dependent tumours |
| FR2656310B1 (en) * | 1989-12-22 | 1992-05-07 | Roussel Uclaf | NEW STEROUID PRODUCTS COMPRISING IN POSITION 10, A SUBSTITUTED THIOETHYL RADICAL, THEIR PREPARATION METHOD AND THE INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| DE4039559A1 (en) * | 1990-12-07 | 1992-06-11 | Schering Ag | FUNCTIONALIZED VINYLAZOLES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THIS VINYLAZOLES AND THE USE THEREOF FOR THE PRODUCTION OF MEDICINAL PRODUCTS |
| GB9212833D0 (en) * | 1992-06-17 | 1992-07-29 | Glaxo Group Ltd | Chemical compounds |
| DK0689536T3 (en) * | 1993-03-16 | 2001-07-30 | Pfizer | naphtahlene |
| JPH07215992A (en) * | 1993-12-07 | 1995-08-15 | Teikoku Hormone Mfg Co Ltd | 6-or 7-substituted androsra-1,4-diene derivative |
| EP0777458B1 (en) * | 1994-09-14 | 2000-12-06 | Central Sheffield University Hospitals NHS Trust | Control of hair growth |
| US5780050A (en) * | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
| AU1793397A (en) * | 1996-03-29 | 1997-10-22 | S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner | Cosmetic or cosmetic preparation for smoothing and tightening the skin in the case of subcutaneous fatty tissue problems, particularly cellulite |
| JP2000515523A (en) * | 1996-07-22 | 2000-11-21 | ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター | Use of sex steroid function modulators in the treatment of wounds and fibrotic disorders |
-
1998
- 1998-03-18 EP EP98104949A patent/EP0943333A1/en not_active Withdrawn
-
1999
- 1999-03-03 CN CNB998064009A patent/CN1168448C/en not_active Expired - Lifetime
- 1999-03-03 ID IDW20002095A patent/ID26965A/en unknown
- 1999-03-03 IL IL13829299A patent/IL138292A/en not_active IP Right Cessation
- 1999-03-03 HU HU0101005A patent/HU226105B1/en not_active IP Right Cessation
- 1999-03-03 AT AT99913218T patent/ATE230995T1/en active
- 1999-03-03 ES ES99913218T patent/ES2190201T3/en not_active Expired - Lifetime
- 1999-03-03 PL PL99343100A patent/PL343100A1/en unknown
- 1999-03-03 RU RU2000126276/15A patent/RU2225206C2/en active IP Right Revival
- 1999-03-03 JP JP2000536383A patent/JP4920822B2/en not_active Expired - Lifetime
- 1999-03-03 SK SK1342-2000A patent/SK285349B6/en unknown
- 1999-03-03 DE DE59904042T patent/DE59904042D1/en not_active Expired - Lifetime
- 1999-03-03 AU AU31434/99A patent/AU751040B2/en not_active Expired
- 1999-03-03 WO PCT/EP1999/001374 patent/WO1999047143A1/en active IP Right Grant
- 1999-03-03 CA CA002324077A patent/CA2324077C/en not_active Expired - Fee Related
- 1999-03-03 BR BR9908885-1A patent/BR9908885A/en not_active Application Discontinuation
- 1999-03-03 KR KR1020007010177A patent/KR100778803B1/en not_active IP Right Cessation
- 1999-03-03 EP EP99913218A patent/EP1063998B1/en not_active Expired - Lifetime
- 1999-03-03 CZ CZ20003256A patent/CZ292643B6/en not_active IP Right Cessation
- 1999-03-03 DK DK99913218T patent/DK1063998T3/en active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11850451B2 (en) | 2011-01-31 | 2023-12-26 | Lucolas-M.D. Ltd. | Cosmetic compositions and methods for improving skin conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1063998A1 (en) | 2001-01-03 |
| DK1063998T3 (en) | 2003-05-12 |
| CZ292643B6 (en) | 2003-11-12 |
| EP1063998B1 (en) | 2003-01-15 |
| JP2002506823A (en) | 2002-03-05 |
| WO1999047143A1 (en) | 1999-09-23 |
| HUP0101005A2 (en) | 2001-08-28 |
| AU751040B2 (en) | 2002-08-08 |
| EP0943333A1 (en) | 1999-09-22 |
| ID26965A (en) | 2001-02-22 |
| ES2190201T3 (en) | 2003-07-16 |
| PL343100A1 (en) | 2001-07-30 |
| HU226105B1 (en) | 2008-04-28 |
| SK13422000A3 (en) | 2001-05-10 |
| IL138292A0 (en) | 2001-10-31 |
| DE59904042D1 (en) | 2003-02-20 |
| ATE230995T1 (en) | 2003-02-15 |
| CN1301165A (en) | 2001-06-27 |
| KR100778803B1 (en) | 2007-11-27 |
| CZ20003256A3 (en) | 2001-04-11 |
| BR9908885A (en) | 2000-11-21 |
| KR20010034603A (en) | 2001-04-25 |
| CA2324077A1 (en) | 1999-09-23 |
| RU2225206C2 (en) | 2004-03-10 |
| CN1168448C (en) | 2004-09-29 |
| JP4920822B2 (en) | 2012-04-18 |
| SK285349B6 (en) | 2006-11-03 |
| IL138292A (en) | 2005-08-31 |
| AU3143499A (en) | 1999-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0189738B1 (en) | Topical compositions for preventing or treating dry skin | |
| James et al. | Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies | |
| US6432940B1 (en) | Uses for androst-5-ene-3β, 17β-diol | |
| KR101403893B1 (en) | New uses for 4,17β-dihydroxyandrost-4-ene-3-one | |
| Sciarra et al. | Plasma testosterone and androstenedione after orchiectomy in prostatic adenocarcinoma | |
| CA2324077C (en) | Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor | |
| US8343948B2 (en) | Medicament for preventing and/or treating mammary carcinoma, containing a steroidal aromatase inhibitor | |
| AU2005301035A1 (en) | Use of androgens to reduce the likelihood of acquiring or to treat skin aging | |
| Mor et al. | Cutaneous complications of hormonal replacement therapy | |
| MXPA00009126A (en) | Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor | |
| USH1551H (en) | Topical composition and method for reducing hair loss from human scalp | |
| Berenguer et al. | The role of lipoaspiration in defeminization of Klinefelter syndrome: a case report | |
| Aksel | Therapeutic approaches to androgen excess | |
| IT8948658A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON HMG-COA REDUCTASE INHIBITORS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY. | |
| NZ210943A (en) | Dehydroepiandrosterone compositons for skin treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |